Log in to save to my catalogue

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolum...

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolum...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2677954103

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Neoadjuvant ipilimumab and nivolumab induces high pathologic response rates (pRRs) in clinical stage III nodal melanoma, and pathologic response is strongly associated with prolonged relapse-free survival (RFS). The PRADO extension cohort of the OpACIN-neo trial (
NCT02977052
) addressed the feasibility and effect on clinical outcome of using...

Alternative Titles

Full title

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2677954103

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2677954103

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-022-01851-x

How to access this item